LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $94.57 Average PT from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $94.57.

Several analysts recently weighed in on LMAT shares. JMP Securities lifted their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target for the company. Barrington Research boosted their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, StockNews.com raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Wednesday.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the transaction, the director now owns 14,114 shares in the company, valued at $1,158,335.98. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.79% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LeMaitre Vascular

A number of large investors have recently made changes to their positions in the stock. NBC Securities Inc. lifted its position in LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares during the period. GAMMA Investing LLC lifted its holdings in shares of LeMaitre Vascular by 57.0% during the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 199 shares during the period. West Oak Capital LLC purchased a new stake in LeMaitre Vascular in the second quarter valued at approximately $58,000. USA Financial Formulas acquired a new position in LeMaitre Vascular in the 3rd quarter worth approximately $60,000. Finally, nVerses Capital LLC raised its position in LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Price Performance

LMAT stock opened at $104.25 on Friday. LeMaitre Vascular has a 12 month low of $47.72 and a 12 month high of $104.81. The firm’s 50-day moving average is $90.66 and its 200 day moving average is $84.41. The company has a market capitalization of $2.34 billion, a PE ratio of 56.97, a P/E/G ratio of 2.49 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period last year, the company posted $0.33 earnings per share. Sell-side analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.61%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.